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Background
Treatment with Cat-PAD (also known as ToleroMune®
Cat, the first in a new class of synthetic peptide
immuno-regulatory epitopes), in an Environmental
Exposure Chamber (EEC) model of cat allergy showed a
persistent treatment effect one year [1] and two years
[2] after administration of only 4 injections over
12 weeks. Here we report the differences in Total Nasal
Symptom Scores (TNSS) between Cat-PAD treatment
arms and placebo two years after treatment started.
Method
Originally 202 subjects were randomised to 4×6nmol
Cat-PAD 4 weeks (wk) apart, 8x3nmol Cat-PAD 2wk
apart, or placebo. EEC challenges were performed at
baseline and 18-22wk. 89 subjects were recruited into a
follow-on study one year after the start of treatment. Of
the subjects who completed the one year EEC challenge,
50 subjects were recruited for a further EEC challenge
100-104wk after the start of treatment. All EEC chal-
lenges consisted of 4 consecutive days of 3 hours (h) of
allergen exposure with Fel d1 levels of circa 50 ng/m3.
The 4 day challenge was designed to ensure late phase
responses were present in the nasal airway. Subjects
scored each of 4 symptoms (Running nose; Sneezing;
Blocked nose; Itchy nose) on a scale of 0-3 every 30 min-
utes during the EEC challenge. These scores were
summed to give a TNSS on a scale of 0-12.
Results
The least squares (LS) mean TNSS was significantly lower
(p <0.05) for 4x6nmol Cat-PAD vs placebo at the follow-
ing EEC challenge: Day 1 at 2h and 2.5h; Day 2 at 2h, 2.5h
and 3h; Day 3 at 1h, 1.5h, 2h, 2.5h and 3h. On Day 4 of
EEC Challenge, when the cumulative allergen challenge is
greatest and late phase responses in the nose are likely to
be maximal, LS mean TNSS was significantly lower for
4×6nmol Cat-PAD vs placebo at 2h (4.818 vs 7.762,
p=0.0090), 2.5h (5.091 vs 7.667, p=0.0290) and 3h (4.818
vs 7.952, p=0.0080) time points. No significant reductions
in LS mean TNSS were observed for 8x3nmol Cat-PAD vs
placebo.
Conclusion
Treatment with 4 injections of 6nmol Cat-PAD over
12wk showed a substantial reduction in patients’ TNSS
that persisted two years after starting treatment. The
treatment effect is substantial under conditions where
late phase responses are expected to be present in the
nasal airway. Cat-PAD is the first in a new class of syn-
thetic peptide immuno-regulatory epitopes and may
confer long-term disease-modification in chronic nasal
airway disease due to cat allergy.
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